FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
SUNOSI
solriamfetol
Peak
Axsome Therapeutics
ORAL · TABLET
2019
NDA
0/100
SUTAB
sodium sulfate, magnesium sulfate, and potassium chloride
Peak
R-Pharm US
ORAL · TABLET
2020
NDA
0/100
SYFOVRE
pegcetacoplan
Peak
Apellis Pharmaceuticals
INTRAVITREAL · SOLUTION
2023
NDA
0/100
SYMDEKO (COPACKAGED)
tezacaftor and ivacaftor
Peak
Vertex Pharmaceuticals
ORAL · TABLET
cystic fibrosis (CF) in patients aged 6 yearsolder
2018
NDA
0/100
SYMJEPI
epinephrine
Peak
INTRAMUSCULAR, SUBCUTANEOUS · SOLUTION
2017
NDA
0/100
SYMPAZAN
clobazam
Peak
ORAL · FILM
2018
NDA
0/100
SYMPROIC
naldemedine
Peak
ORAL · TABLET
2017
NDA
0/100
SYMTUZA
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
Peak
Johnson & Johnson
ORAL · TABLET
2018
NDA
0/100
SYNJARDY
empagliflozin and metformin hydrochloride
Peak
Boehringer Ingelheim
ORAL · TABLET
2015
NDA
0/100
SYNJARDY XR
empagliflozin, metformin hydrochloride
Peak
Boehringer Ingelheim
ORAL · TABLET, EXTENDED RELEASE
2016
NDA
0/100
TABRECTA
capmatinib
Peak
Novartis
ORAL · TABLET
lung cancer
2020
SMNDA
0/100
TADLIQ
tadalafil
Peak
ORAL · SUSPENSION
2022
NDA
0/100
TAFINLAR
dabrafenib
Peak
Novartis
ORAL · CAPSULE
Usage (1lung cancer+1
2013
SMNDA
0/100
TAFINLAR
dabrafenib
Peak
Novartis
ORAL · CAPSULE
Usage (1lung cancer+1
2023
SMNDA
0/100
TAGRISSO
osimertinib
Peak
AstraZeneca
ORAL · TABLET
2015
SMNDA
0/100
TALICIA
omeprazole magnesium, amoxicillin and rifabutin
Peak
ORAL · CAPSULE, DELAYED RELEASE
2019
NDA
0/100
TALZENNA
talazoparib
Peak
Pfizer
ORAL · CAPSULE
2018
NDA
0/100
TARPEYO
budesonide
Peak
Calliditas Therapeutics
ORAL · CAPSULE, DELAYED RELEASE
2021
NDA
0/100
TASCENSO ODT
fingolimod lauryl sulfate
Peak
ORAL · TABLET, ORALLY DISINTEGRATING
2021
NDA
0/100
TASIGNA
nilotinib
Peak
Novartis
ORAL · CAPSULE
equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phaseaccelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant+4
2007
SMNDA
0/100
TAUVID
flortaucipir f-18
Peak
INTRAVENOUS · SOLUTION
2020
NDA
0/100
TAVALISSE
fostamatinib
Peak
Rigel Pharmaceuticals
ORAL · TABLET
2018
SMNDA
0/100
TAVNEOS
avacopan
Peak
ORAL · CAPSULE
2021
NDA
0/100
TAZVERIK
tazemetostat
Peak
ORAL · TABLET
2020
SMNDA
0/100
← PreviousPage 48 of 55Next →